Back

Mechanisms for the benefit of spironolactone in resistant hypertension in the PATHWAY-2 study

28 August 2017 (15:00 - 15:15)
Organised by:
Congress Presentation Part of: Clinical Trial Update 1 Treatment of hypertension ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Bryan Williams

University College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >=160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT
Professor T. Wang (Taipei, TW)
Slides Video
Presentation thumbnail
Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: the AFFIRM Study
Associate Professor M. Proietti (Milan, IT)
Slides Video
Presentation thumbnail
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Doctor R. Giugliano (Boston, US)
Slides Video
Presentation thumbnail
The long-term efficacy and safety of short dual antiplatelet therapy
Professor M. Nakamura (Tokyo, JP)
Slides Video
Presentation thumbnail
Aldosterone Lethal Effects Blocked in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up
Professor F. Beygui (Caen, FR)
Slides Video

Access the full session

Session thumbnail
Clinical Trial Update 1

The Event

Event poster

ESC Congress 2017

28 August 2017 15:00 CET
You may be interested in
thumbnail
Congress Presentation
The effect of spironolactone versus eplerenone on blood pressure targets in resistant hypertension patients.
1 September 2024
thumbnail
Congress Presentation
Adverse effects of spironolactone in long-term treatment of resistant arterial hypertension
1 September 2019
thumbnail
Congress Session
Transforming heart failure care: unlocking new pathways
19 May 2025
thumbnail
Congress Presentation
Sequential nephron blockade with diuretics improves diastolic dysfunction in patients with resistant hypertension, a substudy a the PHARES trial
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources